Printed on 3/17/2026
For informational purposes only. This is not medical advice.
The CHA₂DS₂-VASc score is the most widely used clinical prediction tool for estimating stroke risk in patients with non-valvular atrial fibrillation. It helps clinicians decide whether anticoagulation therapy is warranted by scoring risk factors including heart failure, hypertension, age, diabetes, prior stroke, vascular disease, and sex.
Formula: Score = CHF(1) + Hypertension(1) + Age≥75(2) + Diabetes(1) + Stroke(2) + Vascular(1) + Age 65–74(1) + Female(1)
Select yes or no for each of the eight risk factors. Some factors carry 2 points (age ≥75, prior stroke/TIA) while others carry 1 point.
The calculator sums your points, producing a score from 0 to 9. Higher scores indicate greater annual stroke risk from atrial fibrillation.
Compare your score to guideline thresholds. Men with scores ≥1 and women with scores ≥2 typically warrant anticoagulation per ESC/AHA guidelines.
Cardiologists, internists
At the time of new atrial fibrillation diagnosis, calculate the score to determine whether anticoagulation should be initiated immediately or deferred.
Primary care physicians
Use alongside [HAS-BLED](/tools/has-bled) to weigh stroke prevention benefit against bleeding risk, guiding the shared decision-making conversation with patients.
Hospitalists, clinical pharmacists
Reassess stroke risk during hospital admissions to ensure appropriate anticoagulation is prescribed before discharge.
Follow-up clinic visits
Recalculate yearly as risk factors change — new hypertension, diabetes, or vascular disease diagnosis increases the score and may change management. Also reassess bleeding risk with [HAS-BLED](/tools/has-bled) annually.
Surgeons, proceduralists
Quantify stroke risk to plan perioperative anticoagulation bridging or guide decisions about procedure timing in AFib patients.
Patients with AFib
Understand your personal stroke risk and why your doctor recommends anticoagulation, empowering informed participation in treatment decisions.
ESC 2020 guidelines clarify that female sex is a risk modifier, not an independent risk factor. A woman with a score of 1 (only from sex category) should be treated the same as a man with a score of 0 — no anticoagulation recommended.
High stroke risk doesn't automatically mean anticoagulate. Always [calculate HAS-BLED](/tools/has-bled) to quantify bleeding risk. Even with high HAS-BLED scores, anticoagulation usually still provides net benefit, but it guides closer monitoring.
A history of stroke, TIA, or systemic embolism automatically adds 2 points and typically mandates anticoagulation regardless of other factors. This represents secondary prevention, not just primary prevention.
CHA₂DS₂-VASc is for non-valvular AFib. Patients with mitral stenosis or mechanical heart valves need anticoagulation (often warfarin, not DOACs) regardless of their score.
2023 ESC/AHA guidelines recommend direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin for non-valvular AFib due to better safety profiles and no INR monitoring requirement.
Score hypertension as present if the patient has a diagnosis requiring treatment OR has untreated blood pressure consistently ≥140/90 mmHg. Well-controlled hypertension still counts.
Vascular disease isn't just prior MI — it includes peripheral artery disease, aortic atherosclerosis, and carotid stenosis. Any documented atherosclerotic disease adds 1 point. Use [ASCVD Risk Calculator](/tools/ascvd-risk) or [Framingham Risk Score](/tools/framingham-risk) to assess cardiovascular risk in patients without established disease.
Select either age 65-74 OR age ≥75, not both. A 78-year-old gets 2 points (for ≥75), not 3 points. The calculator handles this automatically.
Score CHF as present if there's documented moderate-to-severe LV systolic dysfunction (EF <40%) or recent heart failure hospitalization. Asymptomatic mild diastolic dysfunction alone is not typically counted.
Men with CHA₂DS₂-VASc of 0 have an annual stroke risk of approximately 0.2%. Guidelines support withholding anticoagulation, though aspirin is no longer recommended as an alternative (provides no benefit with bleeding risk).
CHA₂DS₂-VASc was introduced by Lip et al. (2010) as an improvement over CHADS₂ for better identification of low-risk patients. It is endorsed by ESC (2020), AHA/ACC/HRS (2023), and NICE guidelines for stroke risk stratification in non-valvular AFib. Annual stroke rates by score are derived from the original validation cohort and subsequent large registry studies.
Your CHA₂DS₂-VASc score ranges from 0 to 9 and directly corresponds to an annual stroke risk. A score of 0 in men (or 1 in women where the only point is for female sex) indicates low risk — annual stroke rate is approximately 0.2–0.3%, and anticoagulation is generally not recommended. A score of 1 in men or 2 in women places you in a moderate-risk category where anticoagulation should be considered. A score of 2 or higher in men (3+ in women) carries a clearly elevated stroke risk (roughly 2–15% per year depending on the score) and anticoagulation is generally recommended.
The score should always be interpreted alongside the [HAS-BLED bleeding risk score](/tools/has-bled) to weigh the benefit of stroke prevention against the risk of major bleeding from anticoagulation therapy.
Use this calculator whenever assessing the need for anticoagulation in a patient with non-valvular atrial fibrillation or atrial flutter. It is the standard risk stratification tool recommended by the ESC, AHA/ACC, and most international cardiology guidelines.
It is particularly useful at the time of a new atrial fibrillation diagnosis, during follow-up visits when risk factors may have changed (e.g., new diagnosis of diabetes or vascular disease), and when re-evaluating anticoagulation decisions in patients whose clinical status has evolved.
The CHA₂DS₂-VASc score was designed for non-valvular atrial fibrillation. Patients with valvular AF (especially mitral stenosis or mechanical heart valves) require anticoagulation regardless of their score and should not rely on this tool for decision-making.
The score treats all risk factors as binary (present or absent) and does not weight severity. For example, well-controlled hypertension and refractory hypertension receive the same point. Similarly, a remote TIA and a recent disabling stroke both score 2 points.
Female sex alone (score of 1) is considered a risk modifier rather than an independent risk factor — guidelines do not recommend anticoagulation for women whose only point is sex category. The score also does not account for certain emerging risk factors such as chronic kidney disease, obesity, or obstructive sleep apnea, which may independently increase stroke risk in atrial fibrillation.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Calculate the HAS-BLED score to assess bleeding risk in patients on anticoagulation therapy. Balance stroke prevention against bleeding risk.
CardiologyCalculate the HEART Score to assess the risk of major adverse cardiac events (MACE) in patients presenting with chest pain.
CardiologyCalculate your 10-year risk of cardiovascular disease using the Framingham Risk Score. Based on the landmark Framingham Heart Study data.